Varian Partners with Ballad Health for 10-Year Oncology Initiative in Rural Areas

Varian, a Siemens Healthineers company, has announced a 10-year agreement with Ballad Health to enhance oncology treatment services for patients in rural communities across the Appalachian Highlands, including Northeast Tennessee, Southwest Virginia, northwestern North Carolina, and southeastern Kentucky. This transformative…

Read MoreVarian Partners with Ballad Health for 10-Year Oncology Initiative in Rural Areas

CVS Health® Prepares to Support Customers and Colleagues as Hurricane Helene Approaches

CVS Health® (NYSE: CVS) is proactively preparing for the impending landfall of Hurricane Helene in Florida. The company prioritizes the health and safety of its customers, members, and employees, aiming to provide communities with essential products and services ahead of…

Read MoreCVS Health® Prepares to Support Customers and Colleagues as Hurricane Helene Approaches

Estrella Immunopharma’s ARTEMIS® T-Cell Therapy Leads to Complete Remission in First Patient

Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW), a clinical-stage biopharmaceutical company specializing in ARTEMIS® T-cell therapies targeting CD19 and CD22 for cancer and autoimmune disease treatment, has announced that the first patient in the Phase I/II STARLIGHT-1 clinical trial achieved complete…

Read MoreEstrella Immunopharma’s ARTEMIS® T-Cell Therapy Leads to Complete Remission in First Patient

Iambic Therapeutics Recognized in Endpoints 11 Most Promising Biotech Startups

Iambic Therapeutics, a clinical-stage biotech company harnessing its AI-driven discovery platform, has been named to the 2024 Endpoints News list of “Biotech’s Most Promising Startups.” This annual award highlights innovative life science companies working to develop breakthrough therapies. “By integrating…

Read MoreIambic Therapeutics Recognized in Endpoints 11 Most Promising Biotech Startups

Bristol Myers Squibb Unveils Sotyktu Efficacy Data for Scalp Psoriasis in Two Trials

Bristol Myers Squibb (NYSE:BMY) has announced promising results from the Phase 3b/4 PSORIATYK SCALP trial, which assessed the efficacy of Sotyktu (deucravacitinib) in treating patients with moderate-to-severe scalp psoriasis, including those with less extensive psoriasis. The trial met its primary…

Read MoreBristol Myers Squibb Unveils Sotyktu Efficacy Data for Scalp Psoriasis in Two Trials

Naveris Unveils NavDx® Test Data for HPV-Linked Oropharyngeal Cancer at 2024 AAO-HNS Meeting

Naveris, Inc., a leader in precision oncology diagnostics for viral-induced cancers, announced new data presentation at the 2024 Annual Meeting of the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS), held from September 28 to October 1, 2024, in Miami…

Read MoreNaveris Unveils NavDx® Test Data for HPV-Linked Oropharyngeal Cancer at 2024 AAO-HNS Meeting

New Data: DecisionDx®-SCC Outperforms BWH Staging for High-Risk Skin Cancer Treatment

Castle Biosciences, Inc. (Nasdaq: CSTL), a company focused on improving health through innovative diagnostic tests, announced new data showing that its DecisionDx-SCC test offers clinically significant risk stratification for high-risk SCC patients, particularly those with suppressed immune systems. This enhanced…

Read MoreNew Data: DecisionDx®-SCC Outperforms BWH Staging for High-Risk Skin Cancer Treatment

GE HealthCare’s Flyrcado PET Radiotracer Gains FDA Approval for Better Coronary Artery Disease Diagnosis

GE HealthCare announced that the FDA has approved Flyrcado™ (flurpiridaz F 18) injection, a groundbreaking PET myocardial perfusion imaging (MPI) agent, for detecting coronary artery disease (CAD). Flyrcado offers higher diagnostic accuracy than the widely used SPECT MPI and is…

Read MoreGE HealthCare’s Flyrcado PET Radiotracer Gains FDA Approval for Better Coronary Artery Disease Diagnosis